SCHEMBL7081335

SCHEMBL7081335

CC(=O)c1cc(Cc2ccccc2)cc(Cn2cnccc2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.44
BRD4 O60885 2/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BRDT Q58F21 1/20 0.41
CYP19A1 P11511 2/20 0.39
KDM4C Q9H3R0 1/20 0.38
TBXAS1 P24557 2/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
USP7 Q93009 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
KMT2A Q03164 1/20 0.36
IDO1 P14902 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081463 0.83 LMNA (0.49) LMNABRD4BRD2BRD3BRDT
SCHEMBL7079054 0.80 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2BRD4BRD2BRD3
SCHEMBL7081087 0.78 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2BRD4BRD2BRD3
SCHEMBL27453621 0.77 KDM4C (0.55) ALDH1A1SMN1; SMN2CYP19A1KDM4CTBXAS1
SCHEMBL7667133 0.77 CYP19A1 (0.51) ALDH1A1SMN1; SMN2LMNACYP19A1KDM4C
SCHEMBL7079785 0.76 CYP19A1 (0.56) LMNACYP19A1KMT2A
SCHEMBL6480011 0.72 LMNA (0.62) ALDH1A1SMN1; SMN2LMNAKMT2AMAPT
SCHEMBL12150535 0.72 LMNA (0.62) ALDH1A1LMNAKMT2A
SCHEMBL16891555 0.71 KLKB1 (0.44) LMNACYP11B1CYP11B2KMT2A
SCHEMBL22091424 0.71 MEN1 (0.51) ALDH1A1SMN1; SMN2CYP19A1TBXAS1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 ALDH1A1 145/4885SMN1; SMN2 4337/4885LMNA 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.